Neurontin (Gabapentin)

Gabapentin binds to the α2δ subunit of voltage‑gated calcium channels in the central nervous system. This reduces calcium entry into neurons, leading to decreased release of excitatory neurotransmitters such as glutamate and substance P, which underlies its anticonvulsant and analgesic effects.

The specific dose of Neurontin is individualized by the prescribing clinician based on the patient’s condition, renal function, age, and response to therapy. Dosage adjustments are made during treatment to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for gabapentin in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. If used, the patient should be closely monitored, and breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Neurontin. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Gabapentin is a first‑line agent for several neuropathic pain conditions and differs from tricyclic antidepressants or serotonin‑norepinephrine reuptake inhibitors by targeting calcium channel subunits rather than neurotransmitter reuptake. Its side‑effect profile, renal clearance, and lack of significant anticholinergic activity make it a preferred option for many patients.

Neurontin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Neurontin is taken orally, usually as a tablet or capsule, with or without food. The exact administration schedule—such as once, twice, or three times daily—is determined by the prescriber based on the therapeutic indication and patient-specific factors.

Serious risks include severe allergic reactions (e.g., rash, swelling, difficulty breathing), suicidal thoughts or behavior, and respiratory depression when combined with other central nervous system depressants. Patients should be instructed to seek immediate medical attention if any of these symptoms occur.

Gabapentin is contraindicated in individuals with known hypersensitivity to gabapentin or any of its excipients. Caution is advised for patients with severe renal impairment, as dose adjustments are required, and for those taking other CNS depressants due to an increased risk of sedation.